Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on September 8, 2011. The filing reports the entry into a Material Definitive Agreement by ChromaDex, Inc., a wholly owned subsidiary, with The Regents of the University of California (UC).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only specific financial metric disclosed is a minimum annual royalty payment obligation of $5,000 to UC during the term of the agreement.
Material Changes and Agreement Terms
- Agreement Type: Exclusive License Agreement granting worldwide, exclusive, sublicensable rights to patent rights for the compound Pterostilbene.
- Field of Use: Specified field of use for Pterostilbene, a compound found in blueberries, grapes, and tree bark.
- Consideration: ChromaDex must pay earned royalties on net sales of licensed products and a percentage of attributed income from sublicensing.
- Milestones: Payments are required upon achieving specific product development and regulatory approval milestones.
- Termination: The agreement terminates upon patent expiration, failure to meet pre-development milestones, uncured default, or prior written notice by ChromaDex.
Guidance, Outlook, and Risks
Management has agreed upon a commercialization plan with UC to develop and market licensed products. The filing notes that certain terms of the agreement will be sought for confidential treatment in the upcoming Form 10-Q. No specific financial guidance or risk factors beyond the standard termination clauses were detailed in this summary.
Investor Verification Checklist
- Verify the specific "field of use" restrictions for Pterostilbene in the full agreement.
- Review the upcoming Form 10-Q (for the quarter ended October 1, 2011) for the complete agreement text and confidential terms.
- Confirm the specific dollar amounts or formulas for milestone payments related to product development and regulatory approvals.
- Assess the impact of the $5,000 minimum annual royalty on the company's cash flow projections.